All In Biotech

Drug Trial Radar · NCT06350006

SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor

A Phase Ib/III Study of SHR-A1904 Combinations in CLDN18.2-Positive Advanced Solid Tumor

Last checked: Nov 19, 2026Latest source record: Dec 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

924

Planned (sponsor's estimate)

Start

May 29, 2024

Primary completion

Dec 30, 2027

Study completion Dec 30, 2028

Sponsor

Sponsor type
Industry
First posted
Apr 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study consists of two research phases: Phase Ib (includes dose escalation stage and efficacy expansion stage): To explore the safety, tolerability and initial efficacy of SHR-A1904 in the treatment of CLDN18.2-positive advanced solid tumors, and to determine the recommended dose and recommended population for the Phase III combination study. Phase III: A randomized, Open-Label, multicenter clinical study of SHR-A1904 combined with chemotherapy and immunotherapy Versus chemotherapy combined with immunotherapy for CLDN18.2-positive advanced solid tumors.

Conditions

  • CLDN18.2-positive Advanced Solid Tumor

Interventions

  • SHR-A1904; AdebrelimabDrug

    SHR-A1904 combined with Adebrelimab: SHR-A1904+ Adebrelimab

  • SHR-A1904; CAPOX; AdebrelimabDrug

    SHR-A1904 combined with Adebrelimab and CAPOX (Capecitabine, Oxaliplatin)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of AETime frame: Up to follow-up period, approximately 24 months
  2. Dose Limiting Toxicity (DLT)Time frame: approximately 24 months
  3. Maximal Tolerable Dose (MTD)Time frame: approximately 24 months
  4. Phase III Recommended Dose (RP3D)Time frame: approximately 24 months
  5. Progression-free survival (PFS) assessed by blind Independent Center Review (BICR) based on RECIST 1.1 criteriaTime frame: approximately 36 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.